v
Strides Pharma Science plans to acquire 18 new ANDAs from
Pharmaceutics International Inc, which will significantly expand its
fast-growing niche offerings. A big buy!
v
Going by its strong Q3 results, Apex Frozen Food is likely to
post a robust FY20 performance. Its newly commissioned facilities will boost
its performance further. Accumulate.
v
Britannia Industries posted 23% higher PAT for Q3 on the back of
cost efficiencies. It has also cut trade inventory due to the slowdown. This
evergreen FMCG share deserves a place in every portfolio.
v
Symphony posted an EPS of Rs.8 for Q3FY20 v/s Rs.6 in Q3FY19.
Its 9MFY20 profit has already crossed the FY19 profit. Its future looks bright.
Accumulate.
v
Alkem Laboratories’ Q3 profit nearly doubled to Rs.390 crore.
With a hefty dividend of 1100%, this share merits a buy. Accumulate on dips.
v
Yet another good quarter for UPL with its highest-ever quarterly
profit and an EPS of Rs.9 v/s Rs.6 last year. Buy for the long term.
v
Associated Alcohols & Breweries, the maker of Johnnie Walker
whiskey, has been listed on the NSE. Its share price may rise with a rise in
its volumes.
v
Besides posting fairly good results for Q3, Fermenta Biotech has
declared a 2:1 bonus. A good time to buy.
v
RattanIndia Power, formerly Indiabulls Power, witnessed a
significant turnaround in Q3. Its future looks bright. Accumulate.
v
The infrastructure industry is in for a big boost. It may be
prudent to buy Welspun Enterprises.
v
Bliss GVS Pharma posted exciting results for Q3. This
investor-friendly company is a good long-term bet.
v
The pick-up in steel demand followed by price hikes is likely to
boost the share prices of Tata Steel and NMDC. Accumulate both.
v
Abbott India has begun its northward journey. There are rumours
of a bonus, which is also reflected in its share price movement. Buy.
v
With the huge infra push from the government, efficient cement
stocks like Ramco Cements and Shree Cement are likely to rise further.
v
Despite the 24% dip in Q3 PAT, Hindalco Industries remains a
good investment bet. It is ramping up capacities to meet the anticipated rise
in demand. Accumulate on dips.
v
The Balkrishna Industries counter has seen rising volumes and
price volatility. At Rs.1157, it is an attractive buy.
v
Dr. Reddy’s Laboratories is on an expansion drive. It plans to
acquire 62 domestic brands from Wockhardt for ~Rs.1850 crore. Buy for the long
term.
v
Cochin Shipyard posted 33% higher PAT for Q3FY20. Going by its
performance, it is likely to notch an EPS of Rs.50 for FY20. The stock is
poised to touch Rs.500 on a reasonable P/E of 10x.
v
Going by its Q3 and 9MFY20 results, J.Kumar Infraprojects is
likely to notch an EPS of Rs.30+ for FY20. Its future looks bright. Accumulate.
v
Hinduja Global Solutions may notch an EPS of Rs.90-100 for FY20
if its 9MFY20 results are taken into consideration. Its Q3 profit almost
doubled to Rs.71.34 crore. Accumulate.
v
Going by its H1FY20 results, Kovai Medical Center & Hospital
is expected to notch an EPS of Rs.75 for FY20. Buy for about 30% returns in the
medium term.
v
Considering its 9MFY20 EPS of Rs.168, Vindhya Telelinks is
likely to notch an EPS of Rs.230 for FY20. The stock trades at a P/E of just
3.6x and has the potential to double.
v
Going by its 9MFY20 results, Sasken Technologies is likely to
notch an EPS of Rs.60 for FY20. The stock is poised to touch Rs.720 on a
reasonable P/E of 12x.
Disclaimer:
This is strictly for informational purposes only. It is not a
solicitation to buy, sell in securities or other financial instruments.
FINVESTEDGE do not accept culpability for losses and/or damages arising based
on information in this post. Contact your investment advisor before investing.
Comments
Post a Comment